Marianne Wallenius1, Kjell Å Salvesen2, Anne K Daltveit2, Johan F Skomsvoll2. 1. From the National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, and the National Center for Fetal Medicine, Department of Obstetrics and Gynecology, Trondheim University Hospital; Department of Neuroscience, and Department of Laboratory Medicine, Women's and Child Health, Norwegian University of Science and Technology (NTNU), Trondheim; Department of Global Public Health and Primary Care, University of Bergen; Medical Birth Registry of Norway (MBRN), Division of Epidemiology, Norwegian Institute of Public Health, Bergen, Norway.M. Wallenius, MD, PhD, National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, and the Department of Neuroscience, NTNU; K.Å. Salvesen, MD, PhD, National Center for Fetal Medicine, Department of Obstetrics and Gynecology, Trondheim University Hospital, and the Department of Laboratory Medicine, Women's and Child Health, NTNU; A.K. Daltveit, PhD, Department of Global Public Health and Primary Care, University of Bergen, and the MBRN, Division of Epidemiology, Norwegian Institute of Public Health; J.F. Skomsvoll, MD, PhD, National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital. marianne.wallenius@ntnu.no. 2. From the National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, and the National Center for Fetal Medicine, Department of Obstetrics and Gynecology, Trondheim University Hospital; Department of Neuroscience, and Department of Laboratory Medicine, Women's and Child Health, Norwegian University of Science and Technology (NTNU), Trondheim; Department of Global Public Health and Primary Care, University of Bergen; Medical Birth Registry of Norway (MBRN), Division of Epidemiology, Norwegian Institute of Public Health, Bergen, Norway.M. Wallenius, MD, PhD, National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, and the Department of Neuroscience, NTNU; K.Å. Salvesen, MD, PhD, National Center for Fetal Medicine, Department of Obstetrics and Gynecology, Trondheim University Hospital, and the Department of Laboratory Medicine, Women's and Child Health, NTNU; A.K. Daltveit, PhD, Department of Global Public Health and Primary Care, University of Bergen, and the MBRN, Division of Epidemiology, Norwegian Institute of Public Health; J.F. Skomsvoll, MD, PhD, National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital.
Abstract
OBJECTIVE: To examine the risk of pregnancy loss in women with rheumatoid arthritis (RA). METHODS: Cumulative numbers of early miscarriages (before gestational Week 12), late miscarriages (weeks 12-22), and stillbirths reported to the Medical Birth Registry of Norway in the period 1999-2009. RESULTS: There were 1578 women with RA and 411,130 reference women included in the study. Relative risks of early and late miscarriage in women with RA versus references were 1.2 (95% CI 1.1-1.3) and 1.4 (95% CI 1.1-1.7), respectively. There was no difference in stillbirth. CONCLUSION: The risk of miscarriage was slightly higher among women with RA than in references.
OBJECTIVE: To examine the risk of pregnancy loss in women with rheumatoid arthritis (RA). METHODS: Cumulative numbers of early miscarriages (before gestational Week 12), late miscarriages (weeks 12-22), and stillbirths reported to the Medical Birth Registry of Norway in the period 1999-2009. RESULTS: There were 1578 women with RA and 411,130 reference women included in the study. Relative risks of early and late miscarriage in women with RA versus references were 1.2 (95% CI 1.1-1.3) and 1.4 (95% CI 1.1-1.7), respectively. There was no difference in stillbirth. CONCLUSION: The risk of miscarriage was slightly higher among women with RA than in references.